Phase III trial of albumin-bound paclitaxel [Abraxane] as second-line therapy in patients with pancreatic cancer.

Trial Profile

Phase III trial of albumin-bound paclitaxel [Abraxane] as second-line therapy in patients with pancreatic cancer.

Planning
Phase of Trial: Phase III

Latest Information Update: 28 Jan 2011

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Abraxis BioScience; Celgene Corporation
  • Most Recent Events

    • 28 Jan 2011 Celgene Corporation added as company
    • 07 Apr 2008 New trial record.
    • 01 Apr 2008 This trial is expected to be initiated before the end of 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top